3 results
Approved WMOWill not start
The primary objective of this study is to evaluate the target lesion failure rate of the Conor Sirolimus-eluting Coronary Stent System in lesions up to 28 mm in length in native coronary arteries with a reference vessel diameter of 2.5 mm to 3.5 mm…
Prazosin for the treatment of Obsessive Compulsive Disorder:
An open label, fixed dose add-on study.
To determine whether the addition of the *1 adrenoreceptor antagonist prazosin to SSRI is useful for patients with OCD who do not respond to SRI monotherapy.
Approved WMOCompleted
To determine the safety and effectiveness of the PROMUS Element* Everolimus-Eluting Coronary Stent System (Boston Scientific Corporation [BSC], Natick, MA) for the treatment of patients with up to 2 de novo atherosclerotic lesions